すべての画像(1)

資料

EHU000311

MISSION^® esiRNA

Name: MISSION<SUP>®</SUP> esiRNA
Brand: SIGMA

targeting human IRF1

ログイン組織・契約価格を表示する

すべての画像(1)

About This Item

UNSPSCコード:

41105324

NACRES:

NA.51

おすすめの製品

Slide 1 of 10

1 of 10

SIRNA

MISSION^® siRNA Product Offerings

Sigma-Aldrich

EHURLUC

MISSION^® esiRNA

Sigma-Aldrich

EHUEGFP

MISSION^® esiRNA

Sigma-Aldrich

HPA002018

抗CD36 ウサギ宿主抗体

OLIGO

カスタムDNAオリゴ（Custom DNA Oligos）

Sigma-Aldrich

SIC001

MISSION^® siRNA Universal Negative Control #1

Sigma-Aldrich

S1452

MISSION^® siRNAトランスフェクション試薬

Sigma-Aldrich

SIC002

MISSION^{^®}siRNA Universal Negative Control #2

Millipore

CW0303S03

Milligard^® 0.2 µm（公称）、カートリッジ

Sigma-Aldrich

05-184

Anti-Src Antibody, clone GD11

詳細

製品種目

MISSION^®

形状

lyophilized powder

esiRNA cDNA標的配列

AGTGTACCGGATGCTTCCACCTCTCACCAAGAACCAGAGAAAAGAAAGAAAGTCGAAGTCCAGCCGAGATGCTAAGAGCAAGGCCAAGAGGAAGTCATGTGGGGATTCCAGCCCTGATACCTTCTCTGATGGACTCAGCAGCTCCACTCTGCCTGATGACCACAGCAGCTACACAGTTCCAGGCTACATGCAGGACTTGGAGGTGGAGCAGGCCCTGACTCCAGCACTGTCGCCATGTGCTGTCAGCAGCACTCTCCCCGACTGGCACATCCCAGTGGAAGTTGTGCCGGACAGCACCAGTGATCTGTACAACTTCCAGGTGTCACCCATGCCCTCCACCTCTGAAGCTACAACAGATGAGGATGAGGAAGGGAAATTACCTGAGGACATCATGAAGCTCTTGGAGCAGTCGGAGTGGCAGCCAACAAACGTGGATGGGAAGGGGTACCTACTCAATGAACCTGGAGTCCAGCCCACCTCTGTCTATGGAGACTTTAGCTGTAAGGAGGAGCCAGAAATTGACAGCCCAGGGGGGGATATTGGGCTGAGTCTACAGCGTGTCTTCACAGATCTGAAGAACATGGATGCCACCT

Ensembl |ヒトアクセッション番号

ENSG00000125347

NCBIアクセッション番号

NM_002198

輸送温度

ambient

保管温度

−20°C

遺伝子情報

human ... IRF1(3659) , IRF1(3659)

詳細

MISSION^® esiRNAは、エンドリボヌクレアーゼで調製されたsiRNAです。同じmRNA配列を標的とするsiRNAの不均質混合物です。これらの複数のサイレンシングトリガーにより、高度に特異的で効率的な遺伝子抑制が行われます。

追加情報については、またesiRNAのオプションすべてを表示するには、SigmaAldrich.com/esiRNAにアクセスしてください。

法的情報

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類コード

10 - Combustible liquids

引火点(°F)

Not applicable

引火点(℃)

Not applicable

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA）を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.

Yihe Yan et al.

Cancer immunology, immunotherapy : CII, 69(9), 1891-1903 (2020-05-08)

The objective response rate of immune checkpoint blockade (ICB) in hepatocellular carcinoma (HCC) with anti PD-L1/PD-1 therapy is low. Discovering the signaling pathways regulating PD-L1 might help to improve ICB response rates. Here, we investigate transcription factors IRF-1 and IRF-2

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.

Eri Sugiyama et al.

Science immunology, 5(43) (2020-02-02)

The clinical efficacy of anti-PD-1 (programmed cell death-1) monoclonal antibody (mAb) against cancers with oncogenic driver gene mutations, which often harbor a low tumor mutation burden, is variable, suggesting different contributions of each driver mutation to immune responses. Here, we

Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1.

Jianhua Liu et al.

Arthritis & rheumatology (Hoboken, N.J.), 69(9), 1840-1849 (2017-06-01)

The inflammasome complex is a driver of organ damage in patients with systemic lupus erythematosus (SLE). Although type I interferons (IFNs) are well established as mediators of SLE pathogenesis, their role in inflammasome activation in SLE has not been assessed.

MicroRNA-130b inhibits cerebral ischemia/reperfusion induced cell apoptosis via regulation of IRF1.

Z-D Liu et al.

European review for medical and pharmacological sciences, 24(23), 12334-12341 (2020-12-19)

Cerebral ischemia/reperfusion (CIR) frequently causes serious disabilities and correlates with certain neurological processes. Some studies have shown that microRNAs (miRNAs) exert a neuroprotective effect by modulating the inflammatory process in CIR. However, the biofunction and the mechanism of miR-130b in

Interferon regulatory factor-1 suppresses DNA damage response and reverses chemotherapy resistance by downregulating the expression of RAD51 in gastric cancer.

Lulu Tan et al.

American journal of cancer research, 10(4), 1255-1270 (2020-05-06)

Recent studies have shown that IRF-1 plays a significant role in various tumour-induced chemoresistance, but its role and mechanism in gastric cancer-associated chemoresistance are not clear. Our study showed that IRF-1 expression could reverse gastric cancer-related chemoresistance. Dysregulated DNA repair

資料

MISSION^® esiRNA